interesting company...Do you have clinical link to Phase I and II of ANX-188? I could go and look at clinical.gov but thanks in advance if you have a link.
I like the fact:
1.the company is working on new formulation of approved products...
2.sickle cell anemia is an orphan indication; once approved, can be used off-label
3. strong cash balance
worth a look
ADVENTRX Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing proprietary product candidates. The companys lead product candidate is ANX-188, a rheologic, antithrombotic, and cytoprotective agent, which improves microvascular blood flow and has potential application in treating a range of diseases and conditions, such as complications arising from sickle cell disease. Its other programs comprise Exelbine or ANX-530, a novel emulsion formulation of the chemotherapy drug vinorelbine (Navelbine); and ANX-514, a novel, detergent-free emulsion formulation of the chemotherapy drug docetaxel. The company was formerly known as Biokeys Pharmaceuticals, Inc. and changed its name to ADVENTRX Pharmaceuticals, Inc. in May 2003. ADVENTRX Pharmaceuticals, Inc. was incorporated in 1995 and is based in San Diego, California.